Your AI-Trained Oncology Knowledge Connection!
The combination of JSP191, fludarabine, and low-dose total body irradiation demonstrated facilitation of full donor myeloid chimerism, clearance of minimal residual disease, and a tolerable safety profile in patients with myelodysplastic syndrome or acute myeloid leukemia.
Administration of the SARS-CoV-2 vaccine resulted in heterogeneous immune response in patients with chronic graft-vs-host disease (cGVHD), further highlighting concerns about protection against infection or severe COVID-19 disease in this population
Patients with relapsed/refractory acute lymphoblastic leukemia who underwent matched sibling donor transplants had a significantly higher overall survival at 2 years compared with those who underwent haploidentical stem cell transplant.
The use of 131-iodine generated high rates of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia who did not achieve a complete response following standard therapy.
Evandro D. Bezerra, MD, discusses barriers to enrollment in clinical trials for patients with aggressive B-cell non-Hodgkin lymphoma who have progressed on anti-CD19 CAR T-cell therapy.
Itolizumab decreased levels of cell surface CD6 and increased soluble CD6 in serum in patients with acute graft-vs-host-disease.
Usman Ali Akbar, MD, discusses the systematic review of the efficacy of monoclonal antibodies in adult patients with relapsed/refractory acute lymphoblastic leukemia.
Muhammad Bilal Abid, MD, MRCP, discusses the impact of adaptive lymphodepletion in patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma who received CAR T-cell therapy.
Saurabh Dahiya, MBBS, discusses real-world data observed from a long-term follow-up of axicabtagene ciloleucel in large B-cell lymphoma.
The use of ruxolitinib following an allogeneic hematopoietic cell transplantation was associated with the prevention of serious graft-versus-host disease.
Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.
Myeloablative transplantation with a total body irradiation regimen followed by a graft-versus-host disease prophylaxis regimen led to a low occurrence of GVHD in adult and pediatric patients with hematologic malignancies.
Topical ruxolitinib has shown improved reduction of body surface area of cutaneous chronic graft-vs-host disease vs standard moisturizer vehicle cream, according to interim study results from a poster presented at the 2022 Transplantation & Cellular Therapy Meetings.
Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.
The CAR T-cell therapies axicabtagene ciloleucel, tisagenlecleucel, and lisocabtagene maraleucel evoked responses without increased risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome in patients with primary or secondary central nervous system large B-cell lymphoma.
Ciltacabtagene autoleucel generated deep responses and demonstrated manageable safety in patients with progressive multiple myeloma who were refractory to lenalidomide.
Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.
Mazyar Shadman, MD, MPH, discusses the efficacy of MB-106, a CD20-targeted CAR T-cell therapy in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.
Peter Riedell, MD, discusses the use of axicabtagene ciloleucel in high-risk large B-cell lymphoma, as evaluated on the phase 2 ZUMA-12 trial.
The CAR T-cell therapy axicabtagene ciloleucel produced encouraging responses when used in the first-line treatment of patients with high-risk large B-cell lymphoma.
The utilization of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphomas produced durable outcomes at a 2 years follow-up.
Belimumab could be a potential treatment used to prevent chronic graft-vs-host-disease in patients undergoing allogeneic hematopoietic transplantation by inhibiting BAFF and limiting the survival of aforeactive B cells.
A differentially expressed gene profile was identified in patients with cutaneous nonsclerotic and superficially sclerotic chronic graft-vs-host-disease who responded to treatment with topical ruxolitinib.
Axicabtagene ciloleucel resulted in a longer overall survival benefit in patients with relapsed or refractory large B-cell lymphoma who did not have event-free survival events at months 12 and 24 vs those who experienced events at these time points.
Abatacept significantly reduced steroid-refractory chronic graft versus host disease and the use of prednisone following allogeneic hematopoietic stem cell transplantation.
Mark Walters, MD, discusses the safety profile of betibeglogene autotemcel gene therapy in pediatric patients with transfusion-dependent β-thalassemia, as reported in the phase 3 Northstar-2 and Northstar-3 trials.
Jorge E. Cortes, MD, discusses future directions in the research of CPX-351 in patients with acute myeloid leukemia.
February 17, 2021 — Cord blood–derived natural killer immunotherapy, when paired with high-dose chemotherapy and autologous stem cell transplant, showcased early antitumor activity in patients with B-cell non-Hodgkin lymphoma.
February 16, 2021 - Itolizumab, a humanized IgG1 monoclonal antibody that modulates the activated leukocyte cell adhesion molecule pathway, represents a promising approach for the treatment of patients with newly diagnosed acute graft-versus-host disease.
February 12, 2021 - Ruxolitinib demonstrated a significantly higher overall response rate compared with best available therapy among adolescent and adult patients with chronic graft-versus-host disease.
